Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Dow
Farmers Insurance
Cipla
Express Scripts
Deloitte
Novartis
Accenture
Federal Trade Commission

Generated: January 17, 2018

DrugPatentWatch Database Preview

DORYX Drug Profile

« Back to Dashboard

When do Doryx patents expire, and when can generic versions of Doryx launch?

Doryx is a drug marketed by Mayne Pharma Intl, Warner Chilcott, and Mayne Pharma. and is included in three NDAs. There are five patents protecting this drug and seven Paragraph IV challenges.

This drug has two patent family members in two countries.

The generic ingredient in DORYX is doxycycline hyclate. There are twenty-seven drug master file entries for this compound. Ninety-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
Summary for DORYX
Drug patent expirations by year for DORYX

US Patents and Regulatory Information for DORYX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mayne Pharma Intl DORYX doxycycline hyclate CAPSULE, DELAYED RELEASE;ORAL 050582-002 Aug 13, 2001 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-008 May 20, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-001 May 6, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-006 Dec 19, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-003 Jun 20, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-004 Apr 11, 2013 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mayne Pharma DORYX MPC doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 050795-007 May 20, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DORYX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Delayed-release Tablets 60 mg and 120 mg ➤ Subscribe 9/28/2017
➤ Subscribe Delayed-release Tablets 50 mg ➤ Subscribe 11/5/2015
➤ Subscribe Delayed-release Tablets 80 mg ➤ Subscribe 7/1/2015
➤ Subscribe Delayed-release Tablets 200 mg ➤ Subscribe 5/19/2014
➤ Subscribe Delayed-release Tablets 75 mg and 100 mg ➤ Subscribe PIV received prior to 2/5/2009
➤ Subscribe Delayed-release Tablets 150 mg ➤ Subscribe 12/19/2008
➤ Subscribe Delayed-release Tablets 200 mg ➤ Subscribe 8/12/2013

Non-Orange Book US Patents for DORYX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,016,151,395 ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Federal Trade Commission
Fuji
Medtronic
Express Scripts
Citi
McKesson
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot